/

/

分析EGFR突变型NSCLC患者衍生类器官靶向治疗的敏感性

JoVE 杂志
癌症研究

This content is Free Access.

JoVE 杂志癌症研究

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Please note that all translations are automatically generated. Click here for the English version.

分析EGFR突变型NSCLC患者衍生类器官靶向治疗的敏感性

3,546 Views

•

08:52 min

•

November 22, 2021

DOI:

10.3791/63039-v

DOI:

10.3791/63039-v

•

08:52 min

November 22, 2021

•

6 Views

Dora Barbosa Rabago^1,2,3, Collin M. Blakely^1,2, Franziska Haderk^1,2,3, Trever G. Bivona^1,2,3

¹Department of Medicine,University of California, San Francisco, ²Helen Diller Family Comprehensive Cancer Center,University of California, San Francisco, ³Department of Cellular and Molecular Pharmacology,University of California, San Francisco

Summary

该协议描述了NSCLC患者衍生类器官模型中靶向信号传导抑制剂药物敏感性的标准化评估。

Explore More Videos

Organoids EGFR-mutant NSCLC Targeted Therapies Matrigel Cell Culture Dissociation Trypsinization Centrifugation Cell Counting Cell Suspension 96-well Plate

Read Article